The method of treatment of chronic pancreatitis

 

(57) Abstract:

The invention relates to medicine, namely to therapy, and can be used for the treatment of chronic pancreatitis. Determine the level of serum lipids. In the presence of hyperlipidemia anti-platelet agent used in combination with liponorm within 25 to 30 days. The method allows to reduce the damaging effect of peroxide oxidation of lipids in the cells of the pancreas. This increases the efficiency of treatment of the disease.

The invention relates to medicine, namely to methods of treatment of chronic pancreatitis with lipid metabolism disorders.

There is a method of treatment of chronic pancreatitis, including antispasmodics, inhibitors of proteolytic enzymes, desensitized and detoxication therapy (see Gubergrits A. J., Golubenko O. K., Minevski Y. C. "On peculiarities of clinic and treatment of chronic pancreatitis", "Clinical medicine", 1987, No. 5, S. 76 -81).

The disadvantage of this method is that it does not take into account the state of the microcirculation and, therefore, there is no prevention mikrotrombozov. In addition, this method does not allow for correction of the violation to costly microcirculation introduction of subcutaneous heparin in combination with antiplatelet agents (see Postnikova I.e. and other "Chronic pancreatitis. Clinical and experimental aspects", Publishing house "Lady", Ekaterinburg, 1995, page 166).

The disadvantage of this method, taken as a prototype, is that it does not determine the condition of lipids and hyperlipidemia do not carry out correction to reduce lipid peroxidation and fatty microemboli, reduce sclerotic processes in the blood vessels of the pancreas.

The essence of the invention lies in the fact that according to the method of treatment of chronic pancreatitis involving the use of the antiplatelet agent, determine the level of lipids in the serum and in the presence of hyperlipidemia anti-platelet agent used in combination with liponorm within 25-30 days.

The inventive method takes into account the state of lipid metabolism in chronic pancreatitis. The use of lipotropic drugs can normalize lipid levels, and hence reduce the fat microemboli, to reduce the damaging effect of peroxide oxidation of lipids in the cells of the pancreas, slow sclerotic processes in it.

The method is implemented as follows. The patient is determined by lmii treatment: desegregate (chimes) 5 days intravenously at 10 mg, then 21-25 days oral 25 mg 3 times a day, or 25-30 days orally, in combination with liponorm 100 mg daily oral 25-30 days.

Example 1. Patient P., 36 years old, with a diagnosis of chronic recurrent pancreatitis with impaired pancreatic function in the acute phase, chronic erosive gastritis, had the following biochemical parameters: cholesterol - 9.0 mmol/l, triglycerides - 10.5 mmol/l, LDL - 8.0 g/l Triglycerides: fibrinogen - 1-2, PETIT - 100%, fibrinogen - 6.0 g/l, tolerance to heparin - 14 minutes, time rekaltsifikatsii - 72 seconds, ethanol test - 0-1. Within 25 days the patient received chimes 25 mg orally 3 times a day and lipner 100 mg orally daily. Issued no complaints with the performance of lipids: cholesterol - 5.4 mmol/l, triglycerides - 3.7 mmol/l, LDL - 9.4 g/l Triglycerides: PETIT - 100%, fibrinogen B - 0, fibrinogen - 4.4 g/l, tolerance to heparin - 6 minutes, the time rekaltsifikatsii - 51 second, ethanol test - 0.

Example 2. Patient W., 49 years old, with diagnosis of chronic pancreatitis, a painful form, relapsing course, in the acute phase. Peptic ulcer 12 duodenal ulcer in acute phase, with localization of the ulcer with a diameter of 1 cm on the front wall 12 duodenal ulcer, glyceride - 2.3 mmol/l, LDL - 7,8 g/l Within 30 days received lianor 100 mg orally daily, 5 days chimes 10 mg intravenously, then 25 days - 25 mg 3 times a day orally. Dyspeptic symptoms were on the 2nd day of treatment, pain on the 5th day. Discharged without complaints with the following lipid parameters: cholesterol - 5.8 mmol/l, triglycerides 1.7 mmol/l, LDL - 4.7 g/L.

The method of treatment of chronic pancreatitis involving the use of the antiplatelet agent, characterized in that determine the level of lipids in the serum and in the presence of hyperlipidemia anti-platelet agent used in combination with liponorm within 25 to 30 days.

 

Same patents:

The invention relates to medicine, namely to surgery, and can be used for the treatment of endogenous intoxication in acute pancreatitis

The invention relates to the field of medicine and is suitable for the treatment of cholecystitis, hepatitis, as well as urinary tract infections and gastroenteritis
The invention relates to urology and is intended for the treatment of chronic renal failure

The invention relates to a drug with a long selection preferably in the form of tablets or other dosage forms for oral administration, for slow selection of medicines, gepirone
The invention relates to medicine, Oncology, can be used in the treatment of malignant tumors of the pancreas

The invention relates to new biologically active compounds, methods of treating diseases with their use and pharmaceutical compositions based on these compounds

The invention relates to new sulfonamide of General formula I, where R1-R8A and B have the meanings indicated in the formula, which are inhibitors of endothelin and can be used for the treatment of diseases associated with the activity of endothelin, such as high blood pressure, as well as to pharmaceutical compositions based on

The invention relates to medicine, in particular to surgery, and may find wide use in practice, treatment of long-term healing of wounds and ulcers, accompanied by the emergence of eczematous contact dermatitis
The invention relates to a tool used in traumatology and orthopedics

The invention relates to medicine and can be used in analytical laboratories for standardization and quality control of medicines

Pharmaceutical drug // 2146522
The invention relates to a combined preparation

The invention relates to medicine and can be used for the prevention of postoperative thromboembolic complications
The invention relates to medicine, in particular to pulmonology, and for the treatment of patients with broncho-obstructive syndrome

The invention relates to new aromatic carboxylic acid derivative of the formula (I) where R1radical of formula (a), R2- C2-8- alkanoyl, C2-8- alkyl, C2-8alkenyl, C2-8- quinil or OCH2R3or R1- the remainder of the formula (V), R2- C2-8-alkanoyl, C2-8alkenyl, C2-8- quinil or OCH2R3, R3- C1-6-alkyl, C2-6alkenyl or C2-6-quinil; R4-R9independently from each other hydrogen or C1-5- alkyl, or R8and R9together denote (CRaRb)n, Raand Rbis hydrogen or C1-5-alkyl, n = 1, 2, or 3, and R4- R7have the specified values, or R8and R9together denote (CRaRb)nand R4and R6together is methylene or ethylene which may be substituted by a hydroxyl group, and Ra, Rb, R5, R7and n have the above meanings; R10- carboxyl or C1-6-alkoxycarbonyl, and the dotted bond in the formula (a) is optional, and pharmaceutically acceptable salts of carboxylic acids of the formula I

The invention relates to medicine, to facilities for the treatment of wounds

The invention relates to agriculture, namely, to the drugs designed to combat ectoparasites of farm and domestic animals and can be used in collective farms, state farms, joint stock and cooperative agricultural associations and farms
Up!